ENTOD Pharmaceuticals Obtains Patent for Topical Insulin Eye Drops in Ophthalmology
ENTOD Pharmaceuticals has secured a patent for its topical insulin eye drops, currently in pre-clinical development as a potential new treatment in ophthalmology. The Mumbai-based company highlights this as a milestone in India's pharmaceutical innovation, emphasizing the need for further research to confirm safety and efficacy. Experts note insulin's broader biological roles beyond diabetes, supporting exploration of novel ophthalmic therapies. This development reflects India's growing focus on original drug research and intellectual property creation.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 38/100.
Outlets measured: economictimes, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 19 Sept, 06:01 pm. Other outlets followed.
- 1